QQ客服 官方微博 反馈留言

	Dynamic change of pd-l1 expression on circulating tumor cells in advanced solid tumor patients undergoing pd-1 blockade therapy
	Yue, Chunyan1,3; Jiang, Yubo2; Li, Ping1; Wang, Yuehua1; Xue, Jian4; Li, Nannan4; Li, Da4; Wang, Ruina6,7; Dang, Yongjun6,7; Hu, Zhiyuan1,3,5
刊名	Oncoimmunology
	2018
卷号	7期号:7页码:12
关键词	Advanced solid tumor Circulating tumor cells (ctcs) Immunotherapy Programmed death-ligand 1 (pd-l1) Semi-quantitative analysis
ISSN号	2162-402X
DOI	10.1080/2162402x.2018.1438111
通讯作者	Hu, zhiyuan(huzy@nanoctr.cn) ; Yang, yanlian(yangyl@nanoctr.cn) ; Xu, jianming(jmxu2003@yahoo.com)
英文摘要	Background: tumor pd-l1 levels have predictive value in pd-1/pd-l1 checkpoint blockade therapies, yet biopsies can only provide baseline information. whether pd-l1 expression on circulating tumor cells (ctcs) could serve as an alternative biomarker is of great interest.design: we established an immunofluorescence assay for semi-quantitative assessment of the pd-l1 expression levels on ctcs with four categories (pd-l1(negative), pd-l1(low), pd-l1(medium) and pd-l1(high)). 35 patients with different advanced gastrointestinal tumors were enrolled in a phase 1 trial of a pd-1 inhibitor, ibi308. the ctc numeration and the pd-l1 expression levels were analyzed.results: prior the treatment of ibi308, 97% (34/35) patients had ctcs, ranging from1 to 70 (median 7). 74% (26/35) had pd-l1(positive) ctcs, and 60% (21/35) had at least one pd-l1(high) ctcs. the disease control (dc) rate in pd-l1(high) patients (48%) is much higher than the others (14%). the group with at least 20% abundance of pd-l1(high) ctcs had even higher dc rate of 64% (9/14), with only 14% dc rate for the rest (3/21). we also observed that the count changes of total ctc, pd-l1(postive) ctc and pd-l1(high) ctc correlate quite well with disease outcome (p<0.001, p = 0.002 and 0.007, respectively). in addition, the abundance of pd-l1(high) ctcs at baseline had predicative significance for progression free survival (pfs).conclusions: we revealed that the abundance of pd-l1(high) ctcs at baseline might serve as a predictor to screen patients for pd-1/pd-l1 blockade therapies and measuring the dynamic changes of ctc could indicate the therapeutic response at early time.
WOS关键词	CANCER-PATIENTS ; LUNG-CANCER ; MICROSATELLITE INSTABILITY ; CLINICAL-APPLICATIONS ; OPEN-LABEL ; IMMUNOTHERAPY ; NIVOLUMAB ; DNA ; ATEZOLIZUMAB ; METAANALYSIS
WOS研究方向	Oncology ; Immunology
WOS类目	Oncology ; Immunology
语种	英语
出版者	TAYLOR & FRANCIS INC
WOS记录号	WOS:000433549100002
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/2177489
专题	高能物理研究所
通讯作者	Hu, Zhiyuan; Yang, Yanlian; Xu, Jianming
作者单位	1.Natl Ctr Nanosci & Technol China, CAS Ctr Excellence Nanosci, CAS Key Lab Biomed Effects Nanomat & Nanosafety, CAS Key Lab Standardizat & Measurement Nanotechno, Beijing, Peoples R China 2.Acad Mil Med Sci, Affiliated Hosp Canc Ctr, 8 East St, Beijing 100071, Peoples R China 3.Univ Chinese Acad Sci, Sino Danish Coll, Beijing, Peoples R China 4.Nanopep Biotech Co, Beijing, Peoples R China 5.Fujian Med Univ, Sch Basic Med Sci, Ctr Neurosci Res, Fuzhou, Fujian, Peoples R China 6.Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Metab & Mol Med,Minist Educ, Shanghai, Peoples R China 7.Fudan Univ, Huashan Hosp, Dept Pulm & Crit Care Med, Shanghai, Peoples R China
推荐引用方式 GB/T 7714	Yue, Chunyan,Jiang, Yubo,Li, Ping,et al. Dynamic change of pd-l1 expression on circulating tumor cells in advanced solid tumor patients undergoing pd-1 blockade therapy[J]. Oncoimmunology,2018,7(7):12.
APA	Yue, Chunyan.,Jiang, Yubo.,Li, Ping.,Wang, Yuehua.,Xue, Jian.,...&Xu, Jianming.(2018).Dynamic change of pd-l1 expression on circulating tumor cells in advanced solid tumor patients undergoing pd-1 blockade therapy.Oncoimmunology,7(7),12.
MLA	Yue, Chunyan,et al."Dynamic change of pd-l1 expression on circulating tumor cells in advanced solid tumor patients undergoing pd-1 blockade therapy".Oncoimmunology 7.7(2018):12.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。